Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Comparative Efficacy of Targeted Systemic Therapies for Moderate to Severe Atopic Dermatitis without Topical Corticosteroids: Systematic Review and Network Meta-analysis
Jonathan I. Silverberg, Hwanhee Hong, Jacob P. Thyssen, et al.
Dermatology and Therapy (2022) Vol. 12, Iss. 5, pp. 1181-1196
Open Access | Times Cited: 44

Showing 1-25 of 44 citing articles:

Type 2 chronic inflammatory diseases: targets, therapies and unmet needs
Pavel Kolkhir, Cezmi A. Akdiş, Mübeccel Akdiş, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 9, pp. 743-767
Closed Access | Times Cited: 62
Optimal Use of Jak Inhibitors and Biologics for Atopic Dermatitis on the Basis of the Current Evidence
Masahiro Kamata, Yayoi Tada
JID Innovations (2023) Vol. 3, Iss. 3, pp. 100195-100195
Open Access | Times Cited: 42
The JAK/STAT Pathway and Its Selective Inhibition in the Treatment of Atopic Dermatitis: A Systematic Review
Aikaterini Tsiogka, Maria Kyriazopoulou, George Kontochristopoulos, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 15, pp. 4431-4431
Open Access | Times Cited: 52
Itch and Janus Kinase Inhibitors
Yujin Han, Yu Ri Woo, Sang Hyun Cho, et al.
Acta Dermato Venereologica (2023) Vol. 103, pp. adv00869-adv00869
Open Access | Times Cited: 31
Atopic Dermatitis Yardstick update
Mark Boguniewicz, Luz Fonacier, Emma Guttman‐Yassky, et al.
Annals of Allergy Asthma & Immunology (2023) Vol. 130, Iss. 6, pp. 811-820
Closed Access | Times Cited: 23
Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis
Helena Iznardo, Esther Roé, E. Serra‐Baldrich, et al.
Pharmaceutics (2023) Vol. 15, Iss. 2, pp. 385-385
Open Access | Times Cited: 21
Comparative Efficacy of Targeted Systemic Therapies for Moderate-to-Severe Atopic Dermatitis without Topical Corticosteroids: An Updated Network Meta-analysis
Jonathan I. Silverberg, Hwanhee Hong, Brian Calimlim, et al.
Dermatology and Therapy (2023) Vol. 13, Iss. 10, pp. 2247-2264
Open Access | Times Cited: 20
A New Horizon for Atopic Dermatitis Treatments: JAK Inhibitors
Mircea Tampa, Cristina Iulia Mitran, Mădălina Irina Mitran, et al.
Journal of Personalized Medicine (2023) Vol. 13, Iss. 3, pp. 384-384
Open Access | Times Cited: 19
JAK inhibitors in dermatology: the road travelled and path ahead, a narrative review
Aishwarya Muddebihal, Ananta Khurana, Kabir Sardana
Expert Review of Clinical Pharmacology (2023) Vol. 16, Iss. 4, pp. 279-295
Closed Access | Times Cited: 17
Drug Survival of Upadacitinib and Predicting Factors of Discontinuation in Adult Patients Affected by Moderate-to-Severe Atopic Dermatitis: An Italian Multicenter Analysis
Elena Pezzolo, Michela Ortoncelli, Silvia Ferrucci, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 2, pp. 553-553
Open Access | Times Cited: 4
Efficacy and safety of systemic targeted therapies for atopic dermatitis in children: A systematic review and meta-analysis
Norio Kawamoto, Hiroki Murai, Kazutaka Nogami, et al.
Allergology International (2025)
Open Access
Comparative efficacy of biologics and small molecule drugs in treating pediatric atopic dermatitis in patients aged 2–18 years: A 12–16 week network meta‐analysis of randomized controlled trials
Su‐Boon Yong, Berne Ting, Ikbal Andrian Malau, et al.
Pediatric Allergy and Immunology (2025) Vol. 36, Iss. 2
Closed Access
Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis: Network Meta-analysis of Efficacy
Jonathan I. Silverberg, Thomas Bieber, Amy S. Paller, et al.
Dermatology and Therapy (2025)
Open Access
Real-World Evidence of Tralokinumab Effectiveness and Safety: A Systematic Review and Meta-analysis
Amalie Thorsti Møller Rønnstad, Christopher G. Bunick, Raj Chovatiya, et al.
American Journal of Clinical Dermatology (2025)
Closed Access
Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis
Kim Rand, Juan Manuel Ramos-Goñi, Bülent Akmaz, et al.
Dermatology and Therapy (2023) Vol. 14, Iss. 1, pp. 169-182
Open Access | Times Cited: 10
Upadacitinib for Moderate to Severe Atopic Dermatitis
F.J. Navarro‐Triviño, Sara Alcantara‐Luna, J.J. Domínguez-Cruz, et al.
Immunotherapy (2023) Vol. 15, Iss. 11, pp. 799-808
Closed Access | Times Cited: 9
Patients’ preferences for systemic treatment of atopic dermatitis: safety and efficacy count the most
Marthe‐Lisa Schaarschmidt, Daniel Kromer, Phoebe Wellmann, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access | Times Cited: 2
Interleukin antagonists for atopic dermatitis: a new era of therapy
Aikaterini Tsiogka, Eleni Paschou, Dimitra Koumaki, et al.
Expert Opinion on Investigational Drugs (2024) Vol. 33, Iss. 6, pp. 549-559
Closed Access | Times Cited: 2
Blocking the IL-4/IL-13 Axis versus the JAK/STAT Pathway in Atopic Dermatitis: How Can We Choose?
Laura Marina Calabrese, Martina D’Onghia, Laura Lazzeri, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 7, pp. 775-775
Open Access | Times Cited: 2
JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: Practical pearls for the primary care physician
Albertine Beard, Shannon C. Trotter
Journal of Family Medicine and Primary Care (2024) Vol. 13, Iss. 10, pp. 4128-4134
Open Access | Times Cited: 2
JAK Inhibitors: A New Weapon in the Skin Care Providers' Arsenal.
Osaigbokan Aihie, John A. Dyer
PubMed (2023) Vol. 120, Iss. 1, pp. 45-48
Closed Access | Times Cited: 6
Real-world effectiveness and safety of upadacitinib for the treatment of atopic dermatitis in adult patients switched from dupilumab: A multicenter retrospective study
Jorge R. Georgakopoulos, Dropen Sheka, Brian D. Rankin, et al.
Journal of the American Academy of Dermatology (2023) Vol. 89, Iss. 6, pp. 1308-1311
Closed Access | Times Cited: 6
Assessment of Efficacy and Safety Outcomes Beyond Week 16 in Clinical Trials of Systemic Agents Used for the Treatment of Moderate to Severe Atopic Dermatitis in Combination with Topical Corticosteroids
Jonathan I. Silverberg, April W. Armstrong, Andrew Blauvelt, et al.
American Journal of Clinical Dermatology (2023) Vol. 24, Iss. 6, pp. 913-925
Open Access | Times Cited: 6
Abrocitinib for the Treatment of Atopic Dermatitis
Ana Maria Lé, Melinda Gooderham, Tiago Torres
Immunotherapy (2023) Vol. 15, Iss. 16, pp. 1351-1362
Closed Access | Times Cited: 5
Cost per NNT for upadacitinib in the treatment of patients with moderate-severe atopic dermatitis in Italy
Andrea Chiricozzi, Antonio Costanzo, Anna Levi, et al.
Global & Regional Health Technology Assessment (2024) Vol. 11, Iss. 1, pp. 38-50
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top